Literature DB >> 1794178

Prolonged survival in metastatic malignant melanoma associated with vitiligo.

P Duhra1, A Ilchyshyn.   

Abstract

A metastatic malignant melanoma presenting with axillary lymphadenopathy and without a detectable primary lesion is described in a 66-year-old woman. Extensive vitiligo developed 6 years after this diagnosis. There has been no recurrence of melanoma for 10 years following surgical resection of the lymph nodes. The significance of vitiligo and an elusive primary lesion to the favourable prognosis in metastatic malignant melanoma is discussed.

Entities:  

Mesh：

Year:  1991        PMID： 1794178     DOI： 10.1111/j.1365-2230.1991.tb00383.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


  10 in total

1.  Chronic inflammatory polyneuropathy revealing malignant melanoma.

Authors:  A Rousseau; F Salachas; M Baccard; J Y Delattre; M Sanson
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

2.  Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.

Authors:  Eun Ah Cho; Myung Ah Lee; Hoon Kang; Seung Dong Lee; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

3.  Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.

Authors:  C Naftzger; Y Takechi; H Kohda; I Hara; S Vijayasaradhi; A N Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Fc receptors are required in passive and active immunity to melanoma.

Authors:  R Clynes; Y Takechi; Y Moroi; A Houghton; J V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

5.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

6.  Epidermotropic metastatic melanoma with perilesional depigmentation in an Indian male.

Authors:  Bhavana Doshi; Sunanda Mahajan; Uday S Khopkar; Vidya Kharkar; Prachi Agarwal
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

7.  Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.

Authors:  T A Colella; T N Bullock; L B Russell; D W Mullins; W W Overwijk; C J Luckey; R A Pierce; N P Restifo; V H Engelhard
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

Review 8.  Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.

Authors:  Jing Liu; Stephen J Blake; Mark J Smyth; Michele Wl Teng
Journal:  Clin Transl Immunology       Date:  2014-08-01

9.  High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.

Authors:  G S Ogg; P Rod Dunbar; P Romero; J L Chen; V Cerundolo
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

10.  Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.

Authors:  I Hara; Y Takechi; A N Houghton
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.